FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	Estimated average burden									
hours per respons	e: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ghosh Anirvan</u>				2. Issuer Name and Ticker or Trading Symbol Unity Biotechnology, Inc. [ UBX ]									ationship k all app Direc	,	ng Pe	rson(s) to Is			
(Last)	•	rst) (f	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/25/2024							V	belov	er (give title w) Chief Executive		Other (specify below) e Officer		
285 EAST GRAND AVENUE				4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)								
(Street) SOUTH FRANCE		A 9	4080											V		filed by One filed by Moon		•	
(City)	(Si	rate) (2	Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - Nor	n-Deriva	tive S	Secui	rities	Acq	uired,	Disp	oosed of	, or B	enef	icially	/ Own	ed			
Date					2. Transaction Date (Month/Day/Year)  2. Deemed Execution Date, if any (Month/Day/Year)		Date,	Transaction Disposed (Code (Instr. 5)			es Acquired (A Of (D) (Instr. 3,		4 and Securi Benefi Owned		ties cially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) (D)	or Pi	rice	Report Transa (Instr. 3	action(s) 3 and 4)			(Instr. 4)
Common Stock, \$0.0001 par value 06/25/2				2024			S <sup>(1)</sup>		1,214	14 D		\$1.4	76,929(2)			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)			on Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amou or Numb of Shares	er					

## Explanation of Responses:

- 1. Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
- 2. Includes Restricted Stock Units which vest over time measured from the grant date.

/s/ Alexander Nguyen,

Attorney-in-Fact for Anirvan 06/26/2024

Ghosh

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.